89 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
based on the following criteria:
the then current market value of the underlying Common Shares;
the “Black-Scholes” value of the stock options … , converted into US dollars at the average rate of the corresponding year.
Calculated as of the grant date using the Black-Scholes option pricing model
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
option granted is estimated on the date of grant using the Black-Scholes pricing model. Expected volatility is estimated by considering historic
6-K
EX-99.2
BLU
Bellus Health Inc
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
Executive Officers based on the following criteria:
the then current market value of the underlying Common Shares;
the “Black-Scholes” value … , converted into US dollars at the average rate of the corresponding year.
Calculated as of the grant date using the Black-Scholes option pricing model
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
of grant and is expensed over the award’s vesting period with a corresponding increase to equity. The Company uses the Black Scholes model to calculate … and administrative expenses).
The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes pricing model. Expected
6-K
EX-99.1
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
granted is estimated on the date of grant using the Black-Scholes pricing model. Expected volatility is estimated by considering historic average share
6-K
EX-99.1
n1llfg ocumq8pt9oy3i
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
n2zoyr6kmbl9h3
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.2
mlnm9vxiif61rk7f
7 Apr 22
Notice of Annual Meeting of Shareholders
9:01am
6-K
EX-99.1
03bje5qiba 4whu
5 Apr 22
Current report (foreign)
4:07pm
40-F
EX-99.2
wzhpmlmai
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
tebxx
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
pwflwch id
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
4sz2od2 99te69j47pl
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.1
8wk4 q67g8ganl650p
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.2
bq1e1ddzz 752k07a
9 Apr 21
Notice of Annual Meeting of Shareholders
12:00am
6-K
EX-99.1
9cesqn
8 Apr 21
Bellus HEALTH 2020 ANNUAL REPORT
10:16am
40-F
EX-99.2
rr6a6dz
25 Feb 21
Annual report (Canada)
4:58pm
6-K
EX-99.1
t2rskgx
12 Nov 20
Condensed Consolidated Interim Financial Statements of
4:09pm
6-K
EX-99.1
0r3 ybvjdhbt74rn
13 Aug 20
Condensed Consolidated Interim Financial Statements of
4:01pm
6-K
EX-99.1
zxyvx5q3hooy
14 May 20
Condensed Consolidated Interim Financial Statements of
5:12pm